Cure™

345 PARK AVE SOUTH

Cure Symposia Presents

The Discovery of New Therapeutics Drug Development: A 3 Part Series

Cure Symposia

Cure hosts a series of expert symposia intended to foster education and growth throughout the Cure ecosystem on healthcare, management, innovation, policy, and other relevant subjects. Programming is delivered virtually every Wednesday at 3:30pm EST and with select events hybrid/in person, taking advantage of the Cure's state-of-the-art building, conference and teaching center.

Dynamic, thematic programming includes:

- Policy
- Scientific Themes
- Management Training
- Entrepreneurship Training
- Digital Innovation
- Philanthropic Topics
- Market Opportunities
- Market Access
- Innovation Insights
- Diversity and Inclusion

The Discovery of New Therapeutics Drug Development Series

3-9-2022 Hybrid Session: The Discovery of New Therapeutics Part 1 of 3

This session will provide a high-level overview of the therapeutic discovery process. Specific emphasis will be on defining the goals of discovery programs, designing relevant screening tools and test articles, and preparing for the next stage of development by integrating developability characteristics and biomarkers for clinical translation.

Key themes that will be Included in the discussion:

- Capstone overview of project stage gates from discovery through launch
- Identifying the 6Rs for a new therapeutic discovery program (Right target, Right tissue, Right safety, Right patient, and - Right commercial potential) + Right modality and Right endpoint
- Using a well-defined Target Candidate Profile (TCP) and Target Product Profile (TPP) to guide the drug discovery program
- High level overview of screening cascade design and deciding which candidates to test
- Building developability characteristics into a therapeutic candidate at the discovery stage
- Developing a biomarker strategy for clinical translation

Featuring:
Michele Cleary- Vice President of Academic Outreach, Deerfield Discovery & Development, LLC at Deerfield Management
Christine Brideau- Head of In Vitro Pharmacology, Deerfield Discovery & Development, LLC at Deerfield Management

Registration Link, if you are experiencing any issues please reach out to Tanya Preisser tpreisser@deerfield.com :

https://events.cure.345pas.com/DiscoveryofNewTherapeutics

The Discovery of New Therapeutics Drug Development Series

4-27-2022 Virtual Session: Drug Development – From Discovery Through Market Authorization Part 2 of 3

This unique and in-depth symposium will provide an overview of the interplay between preclinical development, clinical, regulatory and CMC in supporting the progression of novel therapeutics from clinical candidate nomination through market authorization. The discussion will focus a specific emphasis on the design of an IND enabling and clinical development program to achieve the desired target product profile and product label.

Key themes that will be highlighted in the discussion:

- Capstone overview of project stage gates from discovery through launch
- Using the target product profile and product label to guide drug development strategy
- Designing an IND enabling program that integrates clinical goals, safety assessment and CMC
- Overview of clinical phases and clinical study design(s)
- Clinical supply chain considerations
- High-level overview of the interplay between clinical and regulatory including special designations (e.g. fast track, orphan designation)

Featuring:
Ian Hardy- Vice President of Chemistry, Manufacturing & Controls (CMC) for Deerfield Discovery and Development at Deerfield Management
Elizabeth Garner, MD- Chief Medical Officer (CMO) of ObsEva

The Registration Link below will go live at the end of March 2022, if you are experiencing any issues please reach out to Tanya Preisser tpreisser@deerfield.com:

https://events.cure.345pas.com/DrugDevelopmentFromDiscoveryThroughMarket

The Discovery of New Therapeutics Drug Development Series

6-8-2022 Virtual Session: Drug Development – Drug Commercialization and Launch Part 3 of 3

In this lecture we will focus on drug commercialization and launch to maximize the commercial value of a novel therapeutic. Specific emphasis in the session will be placed on discussing early planning for launch and commercialization, highlighting some of the common pitfalls during commercialization and how to avoid them and building an organization for launch success.

Key themes and topics in this session will include:

- Capstone overview of project stage gates from discovery through launch
- Launch planning (how early in development should planning begin)
- Forecasting product launch needs and integrating with manufacture and supply
- Maximizing product value through a successful launch
- Common pitfalls during product commercialization and launch and how to avoid them
- Building an organization to support product launch

Featuring:
Christine Miller - President & Chief Executive Officer at Melinta Therapeutics
Molly Deiss- Senior-Level Pharmaceutical Executive, Healthcare Marketing at Melinta Therapeutics

The Registration Link below will go live at the end of March 2022, if you are experiencing any issues please reach out to Tanya Preisser tpreisser@deerfield.com:

https://events.cure.345pas.com/DrugCommercializationandLaunch